NG00189 – Summary statistics for GWAS of nine individual neuropsychiatric symptoms in mild cognitive impairment and dementia

To access the full dataset, please log into DSS and submit an application.
Within the application, add this dataset (accession NG00189) in the “Choose a Dataset” section.
Once approved, you will be able to log in and access the data within the DARM portal.

The p-value only files are available in the “Open Access Dataset” tab.

Description

Nine individual neuropsychiatric symptom domains (agitation or aggression, anxiety, apathy or indifference, delusions, depression or dysphoria, disinhibition, hallucinations, irritability or lability, nighttime behaviors) measured using the Neuropsychiatric Symptom Inventory Questionnaire were tested for association with single-nucleotide polymorphisms (SNPs) with minor allele frequency > 5% in a sample of 12,806 participants with mild cognitive impairment or dementia.

Participants were sampled from Alzheimer’s Disease Research Centers (ADRCs) throughout the United States and were of European genetic ancestry. For each NPS domain, a participant was classified as a “case” if they experienced the symptom in the month preceding any visit, and as a “control” otherwise. Parallel logistic regressions were performed for each NPS domain while controlling for sex (male v. female), batch (categorical with 15 levels), and the first 10 genetic PCs.

Available Filesets

Name	Accession	Latest Release	Description
GWAS for 9 Neuropsychiatric Symptoms: Full Summary Statistics (application needed)	fsa000159	NG00189.v1	Full Summary Statistics
GWAS for 9 Neuropsychiatric Symptoms: P-values only (open access)	fsa000160	NG00189.v1	P-values only

View the File Manifest for a full list of files released in this dataset.

Consent Level	Number of Subjects
DS-ADRD-IRB-PUB-NPU	NA

Acknowledgment statement for any data distributed by NIAGADS:

Data for this study were prepared, archived, and distributed by the National Institute on Aging Alzheimer’s Disease Data Storage Site (NIAGADS) at the University of Pennsylvania (U24-AG041689), funded by the National Institute on Aging.

Use the study-specific acknowledgement statements below (as applicable):

For investigators using any data from this dataset:

Please cite/reference the use of NIAGADS data by including the accession NG00189.

For investigators using GWAS links APOE to neuropsychiatric symptoms in mild cognitive impairment and dementia – Vattathil, et al. 2025 (sa000076) data:

The authors are grateful to the ADRC, ADNI, and BioVU participants who made this research

possible. This work was supported in full or in part by the following grants to the authors: R01

AG075827, R01 AG072120, IK4BX005219, I01BX005686; R01 AG079170; T32 HG008341;

1R01MH118233. The contents do not represent the views of the U.S. Department of Veterans

Affairs or the United States Government. The Alzheimer's Disease Genetics Consortium supported the collection of samples used in this study through National Institute on Aging (NIA) grants U01AG032984 and RC2AG036528. The NACC database is funded by NIA/NIH Grant U24 AG072122. VUMC BioVU is supported by numerous sources including the NIH funded Shared Instrumentation Grant S10RR025141 and CTSA grants UL1TR002243, UL1TR000445, and UL1RR024975. Data collection and sharing for this project were funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2- 0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

NG00189 – Summary statistics for GWAS of nine individual neuropsychiatric symptoms in mild cognitive impairment and dementia – Vattathil, et al. 2025

Overview

Description

Available Filesets

Related Studies

Consent Levels

Acknowledgement

Acknowledgment statement for any data distributed by NIAGADS:

For investigators using any data from this dataset:

For investigators using GWAS links APOE to neuropsychiatric symptoms in mild cognitive impairment and dementia – Vattathil, et al. 2025 (sa000076) data:

Related Publications

Total number of samples: 0